The tolerability of Octagam® 5% and Octagam® 10%

A non-interventional study on the tolerability of Octagam® 5% and Octagam® 10%

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN02245668

Enrollment

1000

Registered

2011-10-25

Start date

2011-09-01

Completion date

Unknown

Last updated

2022-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Any indication, age, or treatment regimen in which Octagam is prescribed Haematological Disorders

Interventions

The individual observation period for one patient is not limited, PID patients should be observed for a minimum of 10 months, if possible.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All patients treated with Octagam at a participitating site.

Exclusion criteria

Exclusion criteria: Does not meet inclusion criteria

Design outcomes

Primary

Measure	Time frame
Incidence of adverse drug reactions (ADRs)	—

Secondary

Measure	Time frame
Efficacy of treatment	—

Countries

Austria, Brazil, France, Russian Federation, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 26, 2026